In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

J. H. Jorgensen; L. A. Maher; J. S. Redding

doi:10.1007/BF02097209

In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

J. H. Jorgensen, L. A. Maher, J. S. Redding

Department of Pathology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.

Original language	English (US)
Pages (from-to)	91-96
Number of pages	6
Journal	European Journal of Clinical Microbiology
Volume	6
Issue number	1
DOIs	https://doi.org/10.1007/BF02097209
State	Published - Feb 1 1987

ASJC Scopus subject areas

Microbiology
Microbiology (medical)

Access to Document

10.1007/BF02097209

Cite this

@article{c09071c4aeee4c959890f43179469af6,

title = "In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria",

abstract = "The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.",

author = "Jorgensen, {J. H.} and Maher, {L. A.} and Redding, {J. S.}",

year = "1987",

month = feb,

day = "1",

doi = "10.1007/BF02097209",

language = "English (US)",

volume = "6",

pages = "91--96",

journal = "European Journal of Clinical Microbiology and Infectious Diseases",

issn = "0934-9723",

publisher = "Vieweg",

number = "1",

}

TY - JOUR

T1 - In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

AU - Jorgensen, J. H.

AU - Maher, L. A.

AU - Redding, J. S.

PY - 1987/2/1

Y1 - 1987/2/1

N2 - The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.

AB - The in vitro activity of the new lipopeptide antibiotic LY146032 was generally four-fold greater (MIC 90 ≤ 0. 5 μg/ml) than that of vancomycin against methicillin-susceptible or methicillin-resistant Staphybcoccus aureus and coagulase-negative species of Staphylococcus. Enterococci, Streptococcus bovis, group B and viridans streptococci, and Corynebacterium group J-K isolates were inhibited by ≤ 4 μg/ml of LY146032, which represented activity equivalent to or greater than that of vancomycin. Unlike vancomycin, LY146032 was bactericidal for Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes. Due to its bactericidal properties LY146032 appeared to represent an improvement over vancomycin and teicoplanin.

UR - http://www.scopus.com/inward/record.url?scp=0023102328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023102328&partnerID=8YFLogxK

U2 - 10.1007/BF02097209

DO - 10.1007/BF02097209

M3 - Article

C2 - 3032612

AN - SCOPUS:0023102328

SN - 0934-9723

VL - 6

SP - 91

EP - 96

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

IS - 1

ER -

In vitro activity of LY146032 (Daptomycin) against selected aerobic bacteria

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this